Movement Alert｜INSILICO Falls 5.24% in Regular Trading, AI Drug Discovery Pullback Overshadows New Preclinical Candidate Nomination

Market Focus10-15

On October 15, INSILICO fell 5.24% in Regular Trading, trading at HK$39.38, with turnover of HK$399 million.

The move followed continued weakness in the AI drug discovery theme, while the company’s recent nomination of ISM9546 as a preclinical candidate failed to generate a positive share-price response.

INSILICO recently announced ISM9546, an orally available peripheral-restricted VAV1 molecular glue degrader, as its 35th preclinical candidate nomination since 2021, with potential applications in autoimmune diseases including inflammatory bowel disease and rheumatoid arthritis. The candidate was designed through the company’s Pharma.AI platform and showed nanomolar activity in multiple cell studies. However, recent market commentary indicated ongoing profit-taking across the AI drug discovery segment, while an earlier reduction in JPMorgan’s H-share long position to 5.96% also continued to weigh on sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment